Amylyx Pharmaceuticals (NASDAQ:AMLX) versus Theravance Biopharma (NASDAQ:TBPH) Head-To-Head Comparison

Amylyx Pharmaceuticals (NASDAQ:AMLX) and Theravance Biopharma (NASDAQ:TBPH) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends.

Profitability

This table compares Amylyx Pharmaceuticals and Theravance Biopharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Amylyx Pharmaceuticals	N/A	-68.95%	-61.52%
Theravance Biopharma	36.53%	12.20%	6.33%

Analyst Ratings

This is a summary of recent recommendations and price targets for Amylyx Pharmaceuticals and Theravance Biopharma, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amylyx Pharmaceuticals	1	2	8	2	2.85
Theravance Biopharma	0	2	3	2	3.00

Amylyx Pharmaceuticals currently has a consensus price target of $17.25, indicating a potential upside of 23.39%. Theravance Biopharma has a consensus price target of $27.80, indicating a potential upside of 35.74%. Given Theravance Biopharma’s stronger consensus rating and higher possible upside, analysts plainly believe Theravance Biopharma is more favorable than Amylyx Pharmaceuticals.

Institutional & Insider Ownership

95.8% of Amylyx Pharmaceuticals shares are held by institutional investors. Comparatively, 99.1% of Theravance Biopharma shares are held by institutional investors. 12.3% of Amylyx Pharmaceuticals shares are held by company insiders. Comparatively, 6.9% of Theravance Biopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Volatility and Risk

Amylyx Pharmaceuticals has a beta of -0.31, suggesting that its stock price is 131% less volatile than the S&P 500. Comparatively, Theravance Biopharma has a beta of 0.15, suggesting that its stock price is 85% less volatile than the S&P 500.

Earnings & Valuation

This table compares Amylyx Pharmaceuticals and Theravance Biopharma”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amylyx Pharmaceuticals	$87.37 million	17.57	-$301.74 million	($1.80)	-7.77
Theravance Biopharma	$64.38 million	16.12	-$56.42 million	$0.57	35.93

Theravance Biopharma has lower revenue, but higher earnings than Amylyx Pharmaceuticals. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.

Summary

Theravance Biopharma beats Amylyx Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

About Theravance Biopharma

Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs.
Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY.
For more information, please visit www.theravance.com.